Oppenheimer Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $8
Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $21 to $8.
EF Hutton Initiates Coverage On Jasper Therapeutics with Buy Rating, Announces Price Target of $4
EF Hutton analyst Michael King initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Target of $4.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
Jasper Therapeutics Announces FDA Fast Track Designation For JSP191
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Jasper Therapeutics Q2 EPS $(0.29)
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.